Who Qualifies for GLP-1 Weight Loss Treatment? (2026 Eligibility Guide)
FDA-approved GLP-1 medications for chronic weight management have specific eligibility criteria. Here's the full picture, BMI thresholds, qualifying conditions, absolute contraindications, and how the consultation actually works.
The two-tier eligibility framework
FDA labeling for semaglutide (Wegovy) and tirzepatide (Zepbound) for chronic weight management uses a two-tier eligibility model:
- Tier 1, BMI ≥ 30 (obesity). Adults with BMI of 30 or higher qualify on BMI alone, with no comorbidity required.
- Tier 2, BMI 27-29.9 (overweight) + comorbidity. Adults with BMI between 27 and 29.9 qualify if they also have at least one weight-related comorbid condition.
The qualifying comorbidities most commonly accepted:
- Type 2 diabetes (T2D)
- Hypertension (high blood pressure)
- Dyslipidemia (high cholesterol or triglycerides)
- Cardiovascular disease (heart disease, prior heart attack or stroke)
- Obstructive sleep apnea (OSA)
- Polycystic ovary syndrome (PCOS) with insulin resistance
- Non-alcoholic fatty liver disease (NAFLD/MASLD)
Compounded GLP-1 prescribing in our clinic follows the same medical eligibility framework. We don't loosen the criteria for compounded therapy, the BMI and comorbidity thresholds matter regardless of regulatory pathway.
Absolute contraindications, when GLP-1 is not safe
These are conditions that rule out GLP-1 therapy regardless of BMI or comorbidities. The boxed warning on FDA labels exists because of these:
Ready to start?
$199 Skeptics' Trial, see if it works for you
One-time $199 trial with physician evaluation and, only if a prescription is approved and the dispensing pharmacy can fulfill it for the patient's location, one month of compounded semaglutide; the pharmacy confirms packaging and shipping details before fulfillment. No long-term commitment. Standard care starts with a $119 physician review; medication is separate, and compounded semaglutide programs start at $166/month.
Start the 30-day trial- Personal or family history of medullary thyroid carcinoma (MTC). GLP-1 medications carry a class boxed warning for thyroid C-cell tumors based on rodent studies.
- Multiple endocrine neoplasia syndrome type 2 (MEN-2). Same boxed warning rationale.
- Known hypersensitivity to semaglutide, tirzepatide, or any formulation excipient.
- Current pregnancy or breastfeeding. GLP-1 medications are not recommended during pregnancy or lactation; safety data are insufficient.
- Active pancreatitis or history of severe pancreatitis.
Relative contraindications, case-by-case evaluation
These conditions don't automatically rule out treatment but require careful evaluation and may modify the protocol:
- Severe gastroparesis or other significant GI motility disorders. GLP-1 slows gastric emptying, which can worsen these conditions.
- Active suicidal ideation or recent significant psychiatric instability. Some patients on GLP-1 have reported mood changes; the FDA continues to monitor.
- End-stage kidney disease. Dose adjustments and additional monitoring may be required.
- End-stage liver disease. Same.
- Type 1 diabetes. GLP-1 isn't FDA-approved for T1D, though some endocrinologists use it off-label as an adjunct.
- Active gallbladder disease. GLP-1 may increase gallstone risk; monitoring is appropriate.
- Recent bariatric surgery. Coordinated care with the bariatric surgeon is required.
- Eating disorders. History of binge eating disorder, anorexia, or bulimia warrants screening before initiating treatment.
- Diabetic retinopathy. Rapid weight loss can transiently worsen retinopathy; ophthalmology coordination matters.
How the eligibility check actually works at NHWL
- The 2-minute qualifying quiz. Online, no commitment. Captures BMI, primary goal, and a few screening questions.
- The medical intake form. Detailed medical history including current medications, prior surgeries, family history, allergies, and a screening checklist for absolute and relative contraindications.
- Dr. Sharma's review. The physician reviews intake before the visit. If you're clearly not a candidate (an absolute contraindication marked), we tell you before the visit and refund the medication portion of any prepaid trial.
- The initial consultation. 20-30 minute visit (in-person or video) to discuss eligibility, alternatives, and goals.
- The decision. Eligible: prescription is written. Not eligible for GLP-1: we discuss alternatives and may refer you elsewhere.
What if you're not eligible, what then?
If GLP-1 isn't right for you, that doesn't mean we can't help. Some alternatives we discuss:
- Nutrition counseling and structured weight management programs, particularly for patients below BMI 27.
- B12 / lipotropic injection support, energy and metabolic support without GLP-1.
- Referral to bariatric surgery evaluation, for patients with BMI ≥ 40, or BMI ≥ 35 with severe comorbidities.
- Referral to endocrinology or specialty care, for patients whose primary issue is poorly controlled diabetes, hormone imbalance, or another condition that needs different management first.
- Re-evaluation at a future date, if circumstances change (weight gain that brings BMI to threshold, development of a qualifying comorbidity, etc.), we re-evaluate.
Frequently asked questions
What BMI do I need to qualify?
BMI ≥ 30 qualifies on its own. BMI 27-29.9 qualifies if you also have a weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease, PCOS with insulin resistance, NAFLD).
What are the absolute contraindications?
Personal or family history of medullary thyroid carcinoma (MTC), MEN-2 syndrome, hypersensitivity to the active ingredient, current pregnancy or breastfeeding, and active pancreatitis. Severe gastroparesis and other conditions are case-by-case.
Does type 2 diabetes qualify me?
Yes. T2D is one of the qualifying comorbidities. If your endocrinologist already manages your diabetes with brand-name GLP-1, continuing that path is usually preferable.
Does PCOS qualify me?
PCOS itself isn't an FDA indication, but PCOS often presents with insulin resistance and overweight/obesity that meet eligibility under the BMI 27+ comorbidity pathway.
What if my BMI is below 27?
FDA-approved GLP-1 medications for weight management require BMI of at least 27 (with comorbidity) or 30 (without). Below those thresholds, GLP-1 weight loss therapy is not standard medical practice and most physicians will not prescribe it. We won't either. We may suggest other approaches, nutrition counseling, behavioral support, and re-evaluate if your circumstances change.
How does the eligibility check work?
Two steps: (1) the 2-minute qualifying quiz collects basic health information (height, weight, history); (2) the medical intake form gathers your full medical history including contraindications. Dr. Sharma reviews both, and during the initial consultation confirms eligibility, discusses alternatives if you're not a candidate, or writes the prescription if you are.
Will I be denied for a complicated history?
Not automatically. Many conditions are manageable with protocol adjustments. We deny only when there's an absolute contraindication or the risk-benefit doesn't favor proceeding.
This article is informational only and not medical advice. Eligibility for GLP-1 therapy is determined during the medical consultation by Dr. Anjmun Sharma. Individual results vary. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Compounded semaglutide and tirzepatide are not FDA-approved or brand-identical and have not undergone FDA premarket review for safety, effectiveness, or quality. Results vary. Any prescription depends on individualized medical review and lawful pharmacy fulfillment for the patient's location.